Phase III Study of ASP2151 in Patients with Recurrent Herpes Labialis
- Conditions
- Recurrent Herpes Labialis
- Registration Number
- JPRN-jRCT2080224870
- Lead Sponsor
- Maruho Co., Ltd.
- Brief Summary
In this study, a single dose of ASP2151 1200 mg significantly shortened the time to all lesion healing of recurrent herpes labialis over placebo. Amenamevir was well tolerated and showed no clinically major safety concerns.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 1804
Recurrent Herpes Labialis patients
(1)Patients diagnosed with immunodeficiency or
immunocompromised function (such as patients with congenital immunodeficiency, AIDS patients, patients with HIV infection)
(2)Patients with any disorders that should not be enrolled in the sutdy such as;
-severe cardiac disorders
-severe hepatic disorders
-severe pulmonary disorders
-severe blood disorders
(3)Pregnant women, women who may be pregnant, lactating women or women who wish to become pregnant or women who are unwilling to use a suitable method of contraception as directed by the principal investigator or sub-investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method